Viewing Study NCT05227703


Ignite Creation Date: 2025-12-24 @ 7:36 PM
Ignite Modification Date: 2025-12-31 @ 9:33 AM
Study NCT ID: NCT05227703
Status: COMPLETED
Last Update Posted: 2025-10-28
First Post: 2022-01-27
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
Sponsor: AbbVie
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Schizophrenia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Schizophrenia View
None Schizophrenia Spectrum and Other Psychotic Disorders View
None Mental Disorders View